Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation

Zozaya, Néboa; Villoro, Renata; Abdalla, Fernando; Zamora, Santiago Alfonso; Filgueiras, Jesús Balea; Carrillo, J.M. Carrascosa; Sánchez, Olga Delgado; Sinisterra, Francisco Dolz; García-Ruiz, Antonio; Pinto, Pedro Herranz; Manfredi, Antonio; Olmos, José Martínez; Luna, Paloma Morales de los Ríos; Sanz, Lluís Puig; Ros, S.; Hildago, Álvaro

doi:10.2340/actadv.v102.583

Cited by 4 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concerning out-of-pocket expenditures, despite psoriasis treatment being covered by the Spanish National Health System, there is still room for improvement. Health services may vary depending on the area of residence or may not cover all of the patient's needs, having them pay to address them on their own ( 38 ). According to Richard et al ( 25 ) out-of-pocket expenditures of patients with psoriasis in France were more than twice the expenditures for other medical conditions.…”

Section: Discussionmentioning

confidence: 99%

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

Maravilla-Herrera

Merino²,

Zamora³

et al. 2023

Front. Public Health

Self Cite

View full text Add to dashboard Cite

IntroductionPsoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society.MethodsA 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included.ResultsThe annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response.DiscussionA PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

Maravilla-Herrera

Merino²,

Zamora³

et al. 2023

Front. Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…Both public awareness and screening strategies are needed to address the current challenges of early recognition and management of psoriasis in Portugal. Concerning this matter, a recently published study 10 analyzed the unmet needs in the diagnosis and management of psoriasis in Spain from a different range of perspectives. The authors of that study raised awareness about the importance of not only addressing the clinical effectiveness of new treatments, but most importantly, to focus on patient-related challenges (including educational strategies) in the decision-making process, in clinical communication and at a social level.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of Psoriasis in Portugal: A Population-Based Study

Torres

Filipe

Brandão³

et al. 2023

Acta Med Port

View full text Add to dashboard Cite

Introduction: Psoriasis is a common, chronic, and inflammatory skin disorder with a high personal, social and economic burden and important implications for healthcare systems. The aim of this study was to provide an epidemiological characterization of individuals with psoriasis in Portugal.Material and Methods: A large observational, cross-sectional, nationwide, population-based survey study developed by the Portuguese Psoriasis Group of the Portuguese Society of Dermatology and Venereology (GPP-SPDV). A structured questionnaire was designed and applied by experienced interviewers to a random, representative sample of Portuguese individuals with psoriasis and/or psoriatic arthritis. Patients were considered to have psoriasis if they replied positively to one of the following questions: “Does any physician have ever diagnosed you with psoriasis?” or “Do you have a skin disorder characterized by scaling, reddish skin lesions located in the elbows/knees/scalp?”.Results: A total of 6381 individuals were interviewed, of which 283 met the criteria for psoriasis, corresponding to a prevalence rate of 4.4% (95% CI 3.95 – 4.98). Out of the participants that met psoriasis criteria, 24% had suggestive signs/symptoms but did not have a clinical diagnosis established and were not being monitored by a physician. Although more than 70% of participants had active disease (scaling, erythema, or pruritus) and one third had joint symptoms, only 12% were on systemic treatment. Fifty percent of participants with psoriasis (n = 139) had relevant comorbidities (most frequently depression/anxiety and cardiometabolic diseases). Sixteen percent of participants with psoriasis (n = 46) reported that psoriasis interfered with their daily activities (median impact of 5 in a 0 – 10 scale) and 12% mentioned the disease had an impact in their sexual life (median impact of 5 in a 0 – 10 scale).Conclusion: The results of this study suggest that the prevalence rate of psoriasis is likely to be high in Portugal, and several gaps exist at different levels of healthcare delivery to these patients, from diagnosis to treatment. This study provides important data for the future planning of interventions targeting the improvement of psoriasis care in Portugal.

show abstract

“…In einer kürzlich veröffentlichten spanischen Studie wurden insbesondere die Entscheidungsfindung bei der Therapiewahl sowie soziale Auswirkungen benannt. Patienten wünschen Behandlungsoptionen, die Patienten-bezogene Outcomes, Abheilung der Psoriasis, Schnelligkeit des Ansprechens und Anhalten des Therapieerfolges ermöglichen [3].…”

Section: Transfer In Die Praxis Von Prof Dr Uwe Wollina (Dresden)unclassified

Psoriasis: Wie therapeutische Ergebnisse mit ökonomischen und sozialen Auswirkungen in Verbindung stehen

Wollina¹

2023

Kompass Dermatol

View full text Add to dashboard Cite

Introduction: Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society. Methods: A 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included. Results: The annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response. Discussion: A PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis.

show abstract

Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation

Cited by 4 publications

References 33 publications

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

Epidemiology of Psoriasis in Portugal: A Population-Based Study

Psoriasis: Wie therapeutische Ergebnisse mit ökonomischen und sozialen Auswirkungen in Verbindung stehen

Contact Info

Product

Resources

About